Trastuzumab deruxtecan + Standard-of-Care
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Early Breast Cancer
Conditions
HER2-positive Early Breast Cancer
Trial Timeline
Feb 5, 2024 → Jun 1, 2029
NCT ID
NCT05704829About Trastuzumab deruxtecan + Standard-of-Care
Trastuzumab deruxtecan + Standard-of-Care is a phase 2 stage product being developed by AstraZeneca for HER2-positive Early Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05704829. Target conditions include HER2-positive Early Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05704829 | Phase 2 | Active |
Competing Products
20 competing products in HER2-positive Early Breast Cancer